問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉益勝

Recruiting

List

23Cases

2017-05-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-06-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-06-01 - 2026-12-31

Others

Active
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    注射液

Participate Sites
4Sites

Recruiting4Sites

2021-09-06 - 2027-08-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-12-15 - 2026-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-12-15 - 2028-06-29

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-02-26 - 2025-12-10

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-08-01 - 2028-06-30

Others

A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Tecentriq (RO5541267) (Atezolizumab)Avastin (RO4876646) (Bevacizumab)RO7092284 (Tiragolumab)RO7247669 (PD1-LAG3)

Participate Sites
5Sites

Recruiting5Sites

2019-06-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-06-01 - 2026-12-31

Phase I

CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

  • Condition/Disease

    Intermediate stage B or limited advanced stage C hepatocellular carcinoma (HCC)

  • Test Drug

    CSR02-Fab-TF

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB